The number of adverse cardiovascular events, defined as death fromcardiovascular cause, myocardial infarction, stent thrombosis, every second visit to the catheterisation room forre-PCI in the same artery, or stroke, within 1.5 years of PCI, was significantly higher in the CYP2C19 poormetaboliser group treated with clopidogrel (n = 10, 31 %) compared with the poormetaboliser group treated with prasugrel (n = 2, 5 %) (p = 0.003). The gene discussed is CYP2C19; the disease is Stroke.